Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Star Scientific has completed a 'Research and Royalty Agreement' with the Roskamp Institute's affiliate SRQ Bio, under which Roskamp is expected to conduct research on a compound developed by the company's Rock Creek Pharmaceutical subsidiary that medical researchers at the Institute believe may have an application in the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Star Scientific claimed that the preliminary testing of the compound has produced positive results when applied to cells, and the compound is being explored further for its application to treat a variety of neurological conditions, including Alzheimer’s.
The preliminary tests performed by the Roskamp Institute showed that when the compound developed by Rock Creek is applied to cells, B-amyloid is reduced. Also, the compound appeared to encourage new neuronal cell growth. Results in cells do not necessarily translate to human testing, and additional work needs to be completed to determine whether the compound will have significant B-amyloid lowering effects in humans.
Paul Perito, chairman and CEO of Rock Creek, said: “Jonnie R Williams’ decade-long search for innovative ways to reduce tobacco-related harm fortuitously led to a discovery of a compound that respected and knowledgeable medical researchers at Roskamp Institute believe could play a major role in addressing a variety of neurological conditions including Alzheimer’s disease, which has been the primary focus of Roskamp Institute since its formation.”